Video Interview—Allergan’s R&D officer David Nicholson

Nicholson says it's focused on R&D and innovation, and not “egregious price hikes.”

In the second part of our video interview series, we delve into the R&D strategy for Allergan, a company that last year was on the cusp of becoming subsumed in a major merger with Pfizer.

Now it’s forging its own path through a series of small to medium-sized biotech deals to build up its R&D pipeline and go “beyond Botox.” C. David Nicholson, chief R&D officer at Allergan, talked up the company’s innovation push and its growing pipeline.

He explained that Allergan is not looking for “me-too” medications, and talks about fishing in the large external world and engaging the “crowd of brains” to help find the next big innovation. And as Allergan’s executive team pushes for a better deal for patients on pricing, Nicholson talked about the company’s “social contract” on pricing, and not making “egregious price hikes.”


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.


Suggested Articles

The FDA has cleared its first duodenoscope designed to make the intricate, moving and difficult-to-clean parts in the head of the device disposable.

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.